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LAG-3 MEDIATES ACUTE REJECTION & MEMORY IN MOUSE
TRANSPLANTATION
Jeffrey Mark Erfe, Chao Yang, Dorothy Ndishabandi, Ivy Rosales, Rebecca White, Paul S.
Russell, Robert B. Colvin, Joren C. Madsen, and Alessandro Alessandrini.
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
(Sponsored by George Tellides, Section of Cardiothoracic Surgery,
Yale University School of Medicine, New Haven, CT)

ABSTRACT: Lymphocyte Activation Gene-3 (LAG-3) is a soluble protein and transmembrane
protein receptor expressed on lymphocytes such as immunosuppressive regulatory T cells. Our
goal was to evaluate the effect of LAG-3 on transplantation outcomes, specifically rejection and
cellular memory response to donor antigen, by comparing graft survival and IFN-l secretion to
donor antigen in C57BL/6 LAG-3-/- versus wild-type mouse recipients of DBA/2 grafts. We
found that LAG-3 deletion accelerates rejection time and enhances IFN-l secretion among heart
or skin graft recipients. FACS analysis of memory T cells demonstrated disproportionate
increases in effector T cell subsets, consistent with a heightened rejection response. Although the
absence of LAG-3 enhanced rejection of heart and skin grafts, it did not abrogate tolerance of
spontaneously accepted kidney allografts. To further understand the mechanism of LAG-3
signaling and the potential importance of dendritic cells, we cultured donor dendritic cells in a
tolerogenic milieu with recipient T cells and found increased PD-1 and IL-10 expression among T
cells. Lastly, we performed soluble LAG-3 injections and adoptive transfers of LAG-3+/+ cells
into knock-out graft recipients. This demonstrated that the presence of LAG-3 on T cells is
critical for mediation of rejection, while LAG-3 on dendritic cells downregulates donor-specific
IFN-l secretion. Our data suggest that in addition to LAG-3’s effects on proliferation and
activation, LAG-3 may also affect differentiation of precursor CD4+ T cells. Additionally, these
data indicate the importance of dendritic cell-mediated control of the memory response in a LAG3-dependent manner.
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Introduction
Heart transplantation has become a mainstay treatment for patients with severe
end-stage heart failure despite maximum medical therapy. Since 1967, one-year survival
rates have jumped from 30% to 85-90%, and current three-year survival approaches 75%
(1, 2). A significant proportion of late mortality after the first year is attributable to the
usage of broadly immunosuppressive drugs that enable systemic infections and cancers
such as post-transplant lymphoproliferative disease (PTLD) or non-Hodgkin lymphoma
(2). What is needed are new therapies that allow for the targeted induction, proliferation
or activation of narrow cellular and non-cellular immune system elements that
specifically enhance allograft protection while preserving systemic host defenses against
infections and cancers. One possible solution involves the therapeutic alteration or
introduction of glycoprotein moieties to increase the temporally- and locationally-specific
proliferation or activation of regulatory cells. If donor allografts can be modified to
express immunosuppressive glycoprotein moieties, it could downregulate local immune
reactions while preserving systemic immune responses.
A. LAG-3 Structure & Function
Fig. 1: A History of LAG-3
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Discovered in 1990, LAG-3 is primarily known as a Type I cell-surface
membrane receptor and on human chromosome 12p13 is adjacent to CD4, a gene with
which it possesses 20% sequence homology (3). It is believed that LAG-3 and CD4 may
have resulted from a gene duplication and likely share common regulatory elements (4).
LAG-3 binds with greater avidity to the MHC-TCR complex, suggesting that it may
block CD4 pathways and therefore full T cell activation (4, 5). Little is known about the
direct intracellular effects of LAG-3, though the original paper wherein the protein was
described demonstrated that LAG-3 modifies extracellular calcium influx in a CD3/TCRdependent manner (6).
LAG-3 has at least one other splicing variant, a soluble protein (5).
Transcriptional control governs whether LAG-3 is trafficked to the cell-surface as a
receptor or extruded into the serum. Depicted below (Figs. 2, 3) is the structure of the
protein, which is comprised of nine exons, including two stop codons.
Fig. 2: LAG-3 Structure

Fig. 3: LAG-3 Soluble vs. Membrane-Bound

Nature Review Immunology
Nguyen & Ohashi, 2015

Trends in Immunology
Treibel, 2003
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Signaling through the cell-surface isoform occurs on effector T cells after binding
MHC II, which negatively regulates T cell function as shown above (5). T cells signal
downstream via cytoplasmic KIEELE motifs, resulting in decreased cellular proliferation,
cytokine inhibition, and reduced cytolysis, but the intermediary pathway steps have not
yet been described (7). Some DCs are also known to activate after binding LAG-3, either
as a receptor or a soluble protein, using lipid raft microdomains. It has also been
theorized that in addition to interacting with MHC II molecules on DCs, LAG-3 can bind
MHC II that has been acquired by regulatory T cells via trogocytosis (5). LAG-3-MHC
II interactions may be analogous in some ways to CD40L-CD40 interactions. Both
CD40L and CD40 are necessary for IL-12 and IFN-g production in antigen-presenting
cells in vitro and upregulate LAG-3. Similarly, soluble LAG-3 can directly induce DCs
to produce Th1 cytokines and chemokines, such as CCL22 and CCL17, which helps
direct migration of maturing DCs to lymph nodes (3). LAG-3 may also modulate
differentiation of DCs from monocyte precursors (8).

B. Tr1 Regulatory Cells & Immunosuppression
While FOXP3+ regulatory T cells (Tregs) are the quintessential regulatory cells,
other immunosuppressive cell types exist, such as FOXP3- Tr1 cells generated from
CD4+ memory T cells (9). LAG-3 has gained attention in the field of transplant
immunology in part due to its presence on Tr1 cells, which may be beneficial in
dampening the post-transplant immune response. Tr1 cells play an important role in
reducing autoimmune colitis and encephalomyelitis in mice and in controlling reactive
arthritis and multiple sclerosis in humans (10-13). Moreover, Tr1 cells may fill
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immunological niches not served by Tregs. In contrast to FOXP3+ Tregs, Tr1 cells
suppress NLRP3 inflammasome activation via an IL-10-dependent mechanism (14). It
has also been proposed that while natural Tregs are critical early in an immune response
for controlling the magnitude of inflammation, Tr1 cells become important later for
maintaining tolerance (11). The strong potential for Tr1 cells to serve as an
immunomodulatory clinical treatment relates to their higher propensity for inducing local
tolerance against non-self antigens in the periphery, unlike thymus-derived or some
peripherally-derived regulatory T cells (15). This characteristic makes Tr1 cells natural
candidates for controlling inflammation against allogeneic transplants. In fact, recent
studies demonstrate that antigen-specific Tr1 cells are critical for: 1) restoring insulin
production in patients with Type 1 diabetes, 2) facilitating pancreatic islet transplant
tolerance in PTPN22 deficiency, 3) promoting tolerance to mismatched HLA stem-cell
transplants in SCID patients, and 4) preventing mouse skin allograft rejection (12, 15).
Tr1 cells in the periphery have long been characterized as CD4+FOXP3+CD226+
and by a cytokine production profile of IL-10+, IL-4-, TGF-b+, IL-5+, IL-2low/-, IFN-g+/- (9,
15-17). These markers, however, were too broad to efficiently track Tr1 lineage and
movement. In a 2013 Nature paper, Gagliani et al. used differential gene expression in
human blood and immunohistochemical profiles of murine gut isolates to streamline the
identification of Tr1 cells as IL-10-secretors that co-express CD49b and LAG-3 (9).
LAG-3 can be expressed as either a transmembrane protein that downregulates TCRmediated signal transduction in human and mouse lymphocytes or as a soluble molecule
that activates dendritic cells (DCs) and enhances antigen-specific T cell responses (15).
Interestingly, exogenously-induced expression on Tregs of LAG-3, like Tr1 induction,
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requires IL-27 (18). The role of LAG-3 on Tr1 cells has not yet been specified, however.
Moreover, its intracellular pathways have not fully been elucidated, apart from a
description of its cytoplasmic tail receptors (19).
Tr1s generated in vitro using IL-27 and TGF-b co-expressed CD49b and LAG-3
for up to 12 days in culture and up to 13 days after in vivo transfer (9). Markers of Tr1
activation include CD28, CD69, CTLA4, CD25, IL-2Rbg, CD40L, and HLA-DR (11,
15). Tr1 cells can express FOXP3 but only transiently (15). Interestingly,
CD4+CD49b+LAG-3+ differentially express certain receptors (low epidermal growthfactor receptor 2 (Egr2) but high Aryl hydrocarbon receptor (Ahr)), suggesting a
different process of IL-10 production from that principally used by Tregs (9). Tr1 cells
express AhR and require c-Maf, IL-21, and ICOS for IL-27-dependent activation (12, 15,
20, 21). AhR binds c-Maf in Tr1 cells and enhances transcription of IL-10 and IL-21,
secretion of which is important in Tr1 induction as it maintains C-Maf expression
through a feed-forward transcription loop (12). IL-6 has also been implicated in driving
expression of c-Maf and AhR, as well as IRF-4, another critical transcription factor for
IL-10 secretion and Tr1 differentiation, via a STAT3 promoter pathway (15, 22).

C. Galectin Signaling & Tr1 Cells
Galectins are a family of broadly-expressed mammalian carbohydrate-binding
proteins defined by a common b-sandwich structure; they function in multiple
compartments to regulate immune responses by binding glycan ligands, particularly bgalactosides (23, 24). It is plausible that variations in glycosylation patterns affect the
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binding affinity of galectins, which control downstream transcription factors that alter the
likelihood of transplant acceptance.
Galectin-3 (Gal-3) modulates TCR activation threshold on naïve T cells and
galectin-1 (Gal-1) influences TCR signaling in developing thymocytes by altering
negative selection via the ERK pathway (25). Of all known galectins, Gal-1 also has the
strongest evidence for activating and proliferating Tr1 cells by binding CD45 so that
TCR signaling is muted. This is may be due to the prevention of Lck phosphorylation,
allowing Tr1 induction via an intracellular mechanism that involves IL-27. However
further clarification is required (26).
Interestingly, LAG-3, the transmembrane receptor that along with CD49b defines
Tr1 cells, has been shown to bind galectin-3 in vivo to induce immunosuppression by
blocking IFN-g production and CD8+ cytotoxicity (27, 28). If LAG-3 serves a similar
function on Tr1s as it does on T effectors, then it is plausible that LAG-3 on Tr1 cells
may be used to selectively trigger Tr1-mediated graft protection. If true, this would
suggest that existing rates of cardiac allograft tolerance can be further improved using
galectins and possibly custom-designed therapeutics that mimic glycoproteins structures
necessary for activating LAG-3 receptors.

D. Accepting and Rejecting Mouse Allograft Models
Because of its relatively short lifespan, the variety of MHC combinations that can be
tested across strains, and the wide availability of commercially-available genetic
knockouts, the mouse is a suitable model organism to measure the effects of donor-host
incompatibility. It has been shown that the rejection pattern and timing can differ
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markedly both across strain combinations and organ types (29). The particular MHC
combination used in this study, H-2b to H-2d, has been reported to exhibit an average
survival of 9.6±0.4 days for cardiac allografts for C57BL/6 to BALB/c (29). In general,
major allele differences across various strain combinations cause rejection in 7-10 days
(30-32). For the purposes of this study, the heart and skin models are referred to as
“rejection models” because without host immunosuppression they ultimately result in
graft failure. In contrast, in some strain combinations of donors and recipients, kidney
allografts do not undergo failure, even after an extended time period. For instance,
DBA/2 (H-2d) kidneys transplanted into C57BL/6 (H-2b) recipients have been reported to
maintain their function beyond 60 days, for unknown reasons (33). In this study, kidney
allografts between these mouse strains are referred to as an “accepting model” because
they do not typically reject in the long-term even without host immunosuppression.

Statement of Purpose
Though LAG-3 has been investigated in cancer and infectious diseases research,
its role or lack thereof in transplantation needs to be clarified. Specifically, our main
objective is to determine whether LAG-3 simply identifies Tr1 cells or whether it plays a
functional role in mediating rejection or graft-protection. If LAG-3 does modulate
rejection, it is important to investigate its effects in both the short-term (acute rejection)
versus the long-term (immunologic memory). Additionally, characterization of LAG-3’s
disparate effects, if any, on a rejecting model of heart or skin allografts versus a
spontaneously accepting model of kidney allograft is important. Another objective is to
assess whether Gal-3, insofar as it has been reported to be a ligand for LAG-3, modulates
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the function of LAG-3, particularly with respect to the expression of receptors theorized
to be important for graft-protection, such as Foxp3 and IL-10. Finally, if LAG-3 deletion
demonstrates a measurable transplant effect, it will be important to discriminate between
effects mediated via its soluble form or its membrane-bound form (including its
corresponding cell type). We therefore propose the following research aims, hypotheses,
and methods:
Table 1: Research Aims, Hypotheses, & Methods

1.

Research Aim

Hypothesis

To assess whether LAG-

LAG-3 mediates

3 levels influence acute

allograft rejection

allograft rejection

2.

Method(s)
A. Murine heart and skin
transplantations
B. Histologic examination

To assess whether LAG-

LAG-3 mediates T

3 is important for

cell memory

immunologic T cell

development

C. Murine heart and skin
transplantations
D. Splenocyte isolation and

memory

ELISPOT for IFN-g secretion
to donor antigen

3.

4.

To assess whether the

LAG-3 may

E. Murine heart and skin

function of LAG-3

function

differs between

differently

accepting and rejecting

between model

models

types

To assess whether

Gal-3 enhances

A. Co-culture of T cells and DCs

activation of LAG-3, via

the effects of

B. Assessment of IL-10 secretion

Gal-3, affects the

LAG-3 on graft-

G. FACS assessment of Foxp3,

transplantations
F.

Murine kidney transplantations

PD-1, IL-10 expression
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5.

expression of Foxp3,

protective receptor

PD-1, and IL-10

expression

To assess which form of

LAG-3 surface

LAG-3 (receptor or

receptor, due to its

soluble protein) is most

downstream

important for

effects on T cell

transplantation

effectors, is more

A. Adoptive transfer with LAG-3competent T-cells or DCs
B. Pre-treatment with soluble
LAG-3
C. Murine heart and skin

likely to affect

transplantations

transplant
outcomes than
soluble LAG-3

Methods
Bolded initials denote which author performed which methods.

Skin, heart, and kidney transplants
Transplants were performed between allogeneic DBA/2 (H-2d) donors and
C57BL/6 (H-2b) recipients as well as DBA/2 donors and LAG-3-/- recipients on a
C57BL/6 background. In some cases, experimental controls consisted of identical
surgeries performed between syngeneic donor and recipient (C57BL/6 to C57BL/6). All
mice were purchased from Jackson Labs. Shaved skin was harvested from the right
dorsum of donors between the forearm and the hindleg and transplanted within a few
hours to the same location on the recipient (JME). Donor hearts were transplanted
heterotopically in the abdomen by dissecting out the mesentery to the right of the midline
and anastomosing the donor aorta and pulmonary vein to the recipient aorta and inferior
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vena cava, respectively (CY). Donor kidneys were transplanted into the peritoneal
cavity near the midline after complete resection of both recipient kidneys, followed by
attachment of the donor ureter to the recipient bladder (CY). Surgical tools were
autoclaved prior to use, and donors and recipients were operated on using different sets of
sterile tools (JME).

Graft survival assessment
Survival of skin grafts was assessed via visual inspection for evidence of
dessication and necrosis between 8-15 days post-transplant (JME). Heart grafts were
assessed via abdominal palpation (JME). Grafts were harvested (JME) from different
sets of mice at weeks 1 and 2 stained with H&E for pathologic analysis (RW, IR).
Kidney grafts were evaluated by measuring spectrophotometrically the BUN levels of
sera collected from cheek veins (JME). Grafts were categorized as rejected if BUN
exceeded 100 mg/dL (JME).

Adoptive transfer & cytokine pre-treatment
In some experiments, T cells were isolated from spleens and bone marrow
collected using mechanical separation and chemical isolation (Stem Cell Tech) from WT
C57BL/6 animals (JME, DN). DCs were isolated from both spleens and bone marrow
using the same kits (JME). Cells were injected on the same day into tail veins of either
WT or LAG-3-/- animals, one week prior to skin engraftment (JME). Other animals
received soluble LAG-3 (sLAG-3, R&D Systems) injections via peritoneal injection one
week prior to graft placement (JME).
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ELISPOT assay
ELISPOT was performed using PVDF 96-well plates pre-washed with 70%
ethanol, washed three times with PBS, then coated with IFN-g primary antibody diluted
1:100 in PBS for at least 4 hours at room temperature (JME, DN). Isolated cells were
seeded at 100,000 cells/well (JME), along with irradiated 250,000-cell aliquots from
DBA/2, C57BL/6 or C3H mouse spleens (DN). Cells were cultured overnight at 37C in a
CO2 incubator (JME). After 24 hours, plates were washed three times with PBS 0.1%
Tween 20 (JME). Each well received 100 uL of biotinylated IFN-g secondary antibody
diluted 1:100 in PBS for 2 hours at room temperature (JME). After washing, wells were
incubated with streptavidin-horseradish peroxidase (diluted 1:5000) for 1 hour at 37C
(JME). Plates were washed with hydrogen peroxide substrate for 7-10 minutes at room
temperature and dried 24-48 hours (JME). Spots were counted using an automated
protocol in ImmunoSpot Suite 5.0 (JME, AA).

Plasmacytoid dendritic and T cell co-cultures
Splenic and bone marrow lymphocytes were isolated from DBA/2, C57BL/6, or
LAG-3-/- C57BL/6 mice using gentle mechanical techniques followed by red cell lysis
buffer (JME, DN). Cells were resuspended in RPMI and processed using kits for pan-T
or helper T cell isolation or DC purification (Stem Cell Tech) (JME). Cell cultures were
seeded in triplicates on 96-well plates at 50,000 cells/well for DCs and 150,000
cells/well, first with T cells and irradiated DBA/2 splenocytes (for antigen presentation)
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for 24-72 hours in complete growth medium (RPMI, FCS, streptomycin, penicillin,
sodium pyruvate, and non-essential amino acids) at 37 C with 5% CO2 (JME). Some
wells were later combined with DCs after 72 hours, concurrently with the addition of
combinations of various cytokines (Stem Cell Tech, R&D Systems) for an additional 120
hours in these concentrations: IL-15 (100 ng/mL), IL-27 (200 ng/mL), TGF-𝛽 (5
ng/mL), Galectin-1 (100 ng/mL), Galectin-3 (200 ng/mL) (JME). Cell media was
changed every 24 hours for the first 72 hours, and then every 48 hours for the final 120
hours (JME). Cell isolates were analyzed for IL-10 secretion after 5 hours stimulation
using PMA, Ionomycin, and Brefelden A (JME).

Flow Cytometric Staining & Analysis
Cellular staining was conducted with dyes stored at 4C with minimal light
exposure. Prior to extracellular staining, mouse cells undergoing intracellular staining as
well were pre-incubated with 1 ug of anti-mouse CD16/CD32 diluted in 100 uL of FACS
buffer (PBS, 0.5% BSA, 0.1% sodium azide, DI water) for 15 minutes at 4C (JME).
Cell isolates from organ separation and culture wells were transferred in aliquots of at
least 50,000 cells in 1 mL of FACS buffer into 5 mL tubes and were washed at least
twice using serial centrifugation at 1300 RPM for 8 minutes (JME, DN). Extracellular
stains were diluted in aliquots of 1:100 in FACS buffer, and mixed with cells for 30
minutes at 4C with minimal light exposure. Isolates undergoing intracellular (nuclear)
staining were then washed in 500 uL of fixation/permeabilization solution (eBioscience),
then incubated for an additional 60 minutes at room temperature, with minimal light
exposure (JME). Samples were washed twice in 1 mL of permeabilization buffer
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(eBioscience) with centrifugation at 1300 RPM for 8 minutes at 4 C in between washes
(JME). After resuspension in buffer, cells were stained for 30 minutes at room
temperature with minimal light exposure using 1:100 dye aliquots (JME). Cells were
rewashed twice in permeabilization buffer, followed by resuspension in FACS buffer
prior to analysis on a 3-laser 8-color BD FACSVerse Analyzer (JME). Samples were
stored as necessary prior to analysis for up to 48 hours in 10% paraformaldehyde (JME).
Sample gating was conducted in FlowJo v8 (JME, AA).

Statistical Analysis
Kaplan-Meier analyses and Mann-Whitney U Tests were conducted in GraphPad
Prism v7.0 (JME).

Results
Conclusion I: LAG-3 potentiates allograft survival and inhibits T cell memory
generation in transplant rejection models
Transplant outcomes were compared between DBA/2 donor organs placed either
with C57BL/6 or LAG-3-/- C57BL/6 recipients (Figs. 4, 5). Heart grafts survived for an
average of 7 days in LAG-3-/- recipients (n=4) versus an average of 9 days in wild-type
C57BL/6 (WT) recipients (n=3), a difference that was statistically significant via log-rank
testing (P=0.010). Skin grafts survived for an average of 10 days on LAG-3-/- recipients
(n=4) while skin on WT animals (n=4) survived for 13 days on average, a difference that
was statistically significant (P=0.009).
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Kaplan-Meier
Survival,
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Fig. 5: Skin
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Fig. 4: Heart
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Pathology assessments of heart and skin grafts revealed earlier necrosis in both
graft sets (Fig. 6). Although heart grafts placed in LAG-3-/- animals stopped beating a
few days earlier on average, they showed pathologic evidence of ischemia with preserved
tissue architecture in contrast to diffuse disruptive necrosis shown among grafts placed in
WT recipients (Fig. 6). Skin transplants displayed less epithelialization overall as well as
faster necrosis and desiccation for up to two weeks after transplant.
Fig. 6: Heart & Skin Allograft Inspection
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ELISPOT assays were performed for quantifying IFN-g secretion response toward
DBA/2 donor antigen, relative to the response to third-party C3H antigen against which
recipients had not been sensitized (Fig. 7). T cells from LAG-3-/- heart recipient spleens
(n=3) doubled their response, relative to WT T cells (n=3), toward DBA/2 and C3H in
the first two weeks after transplant. The relative LAG-3-/- spot increase compared with
WT cells reached almost ten-fold by the fifth week, for both DBA/2 and C3H antigens.
By the fifth week, spot counts among LAG-3-/- animals at least doubled from the second
week post-transplant. Across all weeks, the difference between WT and LAG-3-/antigens was significant (P=0.003).
Fig. 7: IFN-g Secretion from Splenic T Cells After Heart Transplant
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The response to skin grafts followed a different pattern, though the increase in
antigenic response to DBA/2 was also markedly increased among LAG-3-/- (n=4) relative
to WT (n=4) (Fig. 8). To provide further time for vascularization, assessments were
made at weeks 3-5 post-transplant. As with hearts, response to DBA/2 grafts among
LAG-3-/- animals rose consistently through the fifth week. However, this pattern was not
observed for C3H antigen (Fig. 8). Across all time points, the LAG-3-/- cytokine response
was higher than that of WT (P=0.006).
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Fig. 8: IFN-g Secretion from Splenic T Cells After Skin Transplant
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Conclusion II: LAG-3 deletion alters memory cell distributions and promotes
differentiation of CD44hiCD62lo CD4+ T cells post-transplant
LAG-3-/- skin graft recipients demonstrated altered CD4+ and CD8+
compartments relative to WT recipients (Fig. 9). While at five weeks post-transplant the
proportion of CD44hiCD62lo effector memory cells showed relative stability in the WT
animal, this proportion doubled in the LAG-3-/- animal. The relative proportions of the
memory cell subtypes were grossly unchanged for CD8+ cells (Fig. 9).
Fig. 9: Effector Memory T Cells, Naïve vs. Skin Transplant
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The differences in memory compartments can be appreciated by examining the
trends in CD4+ and CD8+ sub-types across weeks 3-5 for skin graft recipients (Fig. 10).
The percent expression of CD44hiCD62lo memory cells reaches about 30 percent only
for LAG-3-/- CD4+ cells (Fig. 10). Notably, no other memory subtype increased to this
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Conclusion III: LAG-3 deletion causes fibrosis but does not inhibit tolerance
induction of spontaneously accepted renal allografts
Next, we investigated the effect of LAG-3 deletion in an accepting model, given
that the results from heart and skin graft rejection models were consistent with faster
rejection in LAG-3-/- recipients relative to WT recipients (Fig. 11). In certain cases,
kidney transplants are spontaneously accepted despite MHC class differences between
sub-species, notably DBA/2 donor and C57BL/6 recipient. DBA/2 kidney transplants
into LAG-3-/- C57BL/6 mice (n=2), compared against WT mice (n=2), did not show an
appreciable increase in BUN levels, by which rejection was defined as exceeding 100
mg/dL (Fig. 11). Nevertheless, histologic examination of graft tissue revealed greater
fibrosis interspersed throughout and surrounding smaller T cell-rich perivascular regions.
The data also suggest that Tr1 cells may not play a role in the induction of tolerance, as
seen by the allograft kidneys surviving up to 46 days. Whether Tr1 cells are needed for
maintenance of the allograft will require further analysis and monitoring the recipients for
a longer period of time.
Fig. 11: Kidney Fibrosis & BUN, Naïve vs. Kidney Transplant
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Conclusion IV: LAG-3 deletion in a tolerogenic in vitro milieu upregulates PD-1,
FOXP3, and IL-10 on regulatory T cells
To further investigate the results found in the kidney transplants, an in vitro model
of the tolerogenic kidney environment was developed using donor plasmacytoid dendritic
cells and recipient CD4 T cells. Experimental cultures varied by treatment with Gal-3
and either WT or LAG-3-/- to investigate the role of LAG-3 in tolerogenesis as well as the
interplay LAG-3 and its reported ligand, Gal-3 (Fig. 12). Deletion of LAG-3 on CD4+
cells promoted expression of both PD-1 and FOXP3, inhibitory markers associated with
regulatory T cells. Notably, Gal-3 treatment enhanced PD-1 expression only on LAG-3-/cells (Fig. 12). Gal-3 was also independently associated with increased expression of IL10.

Fig. 12: Gal-3 & LAG-3 Effects on CD4 Cell Expression of Foxp3, PD-1, IL-10
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Conclusion V: LAG-3 deletion on T cells are specifically responsible for enhanced
graft rejection
Inspection of skin grafts on days 7 and 10 after transplant showed faster eschar
development in LAG-3-/- versus WT recipients from days 7-10, despite similar levels of
epithelialization and granulation tissue on day 7 (Fig. 13). LAG-3-/- pre-treated with
either dendritic cells or soluble LAG-3 one week prior to transplant also showed greater
eschar formation compared with WT animals. LAG-3-/- animals that received T cells,
however, showed delayed eschar formation and persistence of granulation tissue up to
day 10 (Fig. 13).
Fig. 13: Skin Transplant Survival
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Conclusion VI: Dendritic cells, not T cells, are responsible for heightened memory
response as measured by IFN-g secretion
Measurement of skin allograft responses again demonstrated higher DBA/2 and
C3H cytokine secretion against DBA/2 and C3H antigens in LAG-3-/- relative to WT
recipients (Figs. 14, 15). LAG-3-/- animals that did not receive pre-treatment, as well as
those injected with T cells or soluble LAG-3, showed marked increases in IFN-g
responses, consistent with the results demonstrated in heart graft recipients (see
Conclusion I). In contrast, LAG-3-/- animals that received dendritic cell pre-treatment one
week prior to transplant did not show IFN-g increases and instead demonstrated levels
similar to those of WT animals (Figs. 14, 15).
Fig. 14: DBA/2 Response, Skin Allograft

Fig. 15: C3H Response, Skin Allograft
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Discussion
LAG-3 is a soluble and transmembrane protein whose significance in solid organ
transplantation has not been fully characterized. As a classificatory marker for Tr1s, a

25

subset of inducible peripheral regulatory T cells, an important aim of this study is to
determine whether LAG-3 does not functionally mediate the rejection process and
therefore simply identifies specific classes of regulatory cells, or whether LAG-3 directly
mediates allograft rejection. Because rejection can take multiple forms, most applicably
either acute or chronic rejection, subsequently parsing out the time-dependent effect of
LAG-3 deletion becomes a necessary goal. This we achieved by examining LAG-3
deletion on short-term graft survival as well as long-term immunological memory, as
measured by IFN-l secretion in response to donor antigen.
An important corollary is that to the extent there is a measurable effect of LAG-3
on transplant outcomes, these effects likely depend on a specific isoform, either soluble
or membrane-bound, and/or cell type. This we investigated by re-introducing LAG-3
either as a soluble protein or as a membrane-bound protein attached to either T cells or
dendritic cells and trending transplant and memory outcomes. In the context of
investigating the effects of LAG-3, it became clear that LAG-3’s effects may differ based
on whether the mouse transplant model of choice was a rejecting model (heart or skin) or
an accepting model (kidney). Due to an ambiguous effect of LAG-3 deletion in the
accepting model, we created a T cell-dendritic cell co-culture environment mimicking
that in the accepting model and noted the effect of LAG-3 deletion on immunological
surface receptors.
Given the aims outlined above, this study generated six conclusions (see Results)
which have implications for our understanding of how LAG-3 functions immunologically
in a transplantation context. Additionally, the findings of the study delineate a clearer
role for LAG-3 and its molecular functions with respect to important inhibitory markers,
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particularly PD-1, FOXP3, and IL-10, as well as dendritic cells. These conclusions and
their implications will be discussed in turn.

Effects of LAG-3 on allograft survival and T cell memory generation in rejection models
Our first results demonstrate that LAG-3 deletion accelerates rejection of cardiac
and skin allografts by a few days in either case. H&E staining of rejected cardiac
allografts shows greater intercellular lymphocytic infiltration and distortion of graft
parenchyma. Grafts in LAG-3-/- recipients, on the other hand, show relatively preserved
architecture but appear to develop greater vascular occlusion, suggesting that these grafts
reject faster, possibly due to an ischemic T cell-mediated process. Published evidence
suggests that memory T cells directly mediate cardiac allograft vasculopathy in RAG-1-/B/6 (H-2b) recipients of Balb/c (H-2d) cardiac allografts in an OX40/OX40L-dependent
manner (34). OX40L blockade in this study was associated with impairment of T-cellmediated vascular injury, a finding reflected in human patients with CAV. Activated
memory T cells present in human coronary arteries generate a significant proportion of
infiltrating mononuclear cells contributing to vascular inflammation (35). Furthermore,
the causality may be bidirectional: while inflammation can lead to ischemia so can
ischemia lead to inflammation. In a separate study of allogeneic cardiac transplants
among rats, the degree of vessel injury in ischemic injured allografts at 90 days posttransplant was significantly greater than that in non-ischemic injured allografts (36). It is
possible therefore that ischemia can lead to greater degrees of inflammation and viceversa, generating a positive feedback mechanism leading ultimately to chronic rejection.
Our findings corroborate the theory of T-cell-mediated vascular injury but with the
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important distinction that these findings occurred in the knockout animals on a faster
timescale, suggesting that LAG-3 inhibits the ischemic and inflammatory effects of T
cells to a graft. This is consistent with broadly accepted notions of LAG-3, namely that it
retards T cell activation, proliferation, and inflammatory cytokine generation (5, 19, 3740).
Consistent with the findings in heart, the model of skin engraftment showed that
LAG-3-/- animals accelerated rejection as evidenced by greater epithelial disruption by
day 9 post-transplant and older scar formation by day 13. This additional evidence from
a separate type of rejection model supports the theory that the absence of LAG-3 plays a
measurable role in accelerating graft rejection. Both the heart and skin models also
generated significantly higher levels of IFN-𝛾 by T cells isolated from spleen in response
to donor antigen (1.5-2.5x higher) at least three weeks out from surgery. While the
cytokine production of LAG-3-/- T cells in response to third-party C3H stimulators also
exceeded that of wild-type T cells, suggesting a baseline level of LAG-3-dependent
inhibition of T cell activity, the cytokine effect was proportionally higher for heart
allografts at week 5. Thus, the blanket effect on all cellular responses due to LAG-3
deletion, consistent with the literature as described above, is shown by the effect on thirdparty. However, one novel finding of this study is the increased effect in LAG-3
knockout animals, which cannot be accounted for by increased activity alone, but rather a
combination of either increased differentiation or increased cellular generation.
The second conclusion suggests that LAG-3 affects production of memory T cell
differentiation. In the inflammatory milieus after skin and heart transplants, LAG-3
deletion increases splenic memory T cells as measured by IFN-𝛾 ELISPOT secretion.
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FACS analysis of naïve WT and LAG-3-/- animals compared with skin transplant
recipients 5 weeks later shows that transplantation increases the differentiation of
CD44hiCD62Llo CD4+ memory T cells, a type of effector memory cells. Memory T
cells originate from naive thymic CD25- T cells that can develop into CD25+ effector T
cells (41). In mice some of these T cells can become memory T cells, as distinguished by
CD62L (L-selectin) and CD44 (H-CAM) (42). Memory cells express low levels of Lselectin in contrast to naïve cells; however, naïve cells express low levels of HCAM
relative to memory cells. Effector memory cells have been broadly associated with
inflammation secondary to numerous causes, such as infection, allergens, and chemical
irritants (42, 43). Recently, the field has also highlighted the importance of memory T
cells in mediating graft rejection and their role as a significant barrier to tolerance
induction in clinical transplantation, since these alloreactive cells reside in and recirculate
among peripheral non-lymphoid tissues associated with the graft (15, 44, 45). Our
findings in this study suggest that LAG-3 dampens the effect of memory T cell
generation, which occurs at an exceedingly higher rate when LAG-3 is deleted. This
novel finding is particularly important for transplantation because co-stimulation
blockade, a staple of immunological therapies, does not adequately control the responses
of memory T cells (45). These results are mutually substantiated by those mentioned
earlier, specifically that memory cells have been associated with chronic allograft
vasculopathy. It is possible that the same mechanism that upregulates acute cellular
graft rejection at the vascular level also produces a greater level of memory T cells in the
long-term.
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Effects of LAG-3 on allograft survival and cell differentiation in an accepting model
Spontaneously accepted renal allografts show smaller Treg-rich regions with
higher fibrosis, but BUN levels do not reach a rejection level (>100 mg/dL) by 6 weeks.
Beyond this time period, long-term graft follow-up and analysis may reveal a different
pathology. The difference in these observed allograft acceptance results could in part be
dependent on the varying roles of LAG-3 on different T cell populations in either a
rejection or tolerogenic milieu. It has been established that T cell fates are highly
dependent on the cytokine microenvironment to which they are exposed at various stages,
and that ultimately graft survival in a host depends on whether its T cells largely take on
a pro-inflammatory or pro-tolerant phenotype (46). While the BUN findings did not
suggest a rejection process, cellular histology did demonstrate increased parenchymal
fibrosis indicative of a chronic inflammatory process. One explanation for this finding
could be that while LAG-3 does indeed accelerate inflammation, it has a countervailing
and separate effect in a microenvironment of cytokines that are tolerogenic, or at least
graft-protective.
In spontaneously accepted renal allografts, in which regulatory cytokines or
proteins such as IL-27, TGF-b, and Gal-1 are upregulated or conserved (unpublished
observations based on RNA transcript analysis), stimulation of CD4+ naïve cells with
tolerogenic allogeneic DCs depends in part on LAG-3. In in vitro assays that replicate
this tolerogenic milieu, LAG-3 deletion increases expression of PD-1 and IL-10 on
regulatory T cells analyzed by FACS staining. At first glance, this finding contrasts with
past research that shows that the development of naïve CD4+ cells can be shunted toward
a regulatory phenotype, most notably Tr1 cells, in LAG-3 dependent processes in the gut

30

and in tumors (18, 47, 48). However, it may be that with germline deletion of LAG-3 an
earlier T cell development stage is obviated or altered such that a greater proportion of T
cell precursors ultimately become graft-protective. This theory is consistent with the
evidence presented previously LAG-3 deletion functionally produces a higher proportion
of memory T cells. The principal difference in these two cases is the cytokine milieu. In
a pro-rejection microenvironment such as that of mouse heart or skin allotransplantation,
then the net effect of germline LAG-3 deletion is to produce an anti-graft effect; whereas,
in the tolerant microenvironment of kidney allotransplantation, then the corresponding
net effect is a sustained immunoprotective response. This theory is encapsulated by the
overarching model presented below:
Fig. 16: Suggested Model of LAG-3 Control of T Cell Differentiation

One theory by which this may occur is that LAG-3 may depress differentiation of T cells
by blocking co-stimulatory or activating MHC or glycoprotein signals. Without LAG-3,
cells are more likely to differentiate. This model explains how an absence of LAG-3 in
the in vitro experiments in this study can generate relatively higher expression of PD-1,
IL-10, and FOXP3 on FACS analysis. The relative proportions of certain cellular
subtypes, primarily FOXP3 regulatory T cells and peripheral Tr1 cells, are greatly
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enhanced in the absence of LAG-3 if LAG-3 exerts control through an undescribed
mechanism over the differentiation of CD4+ precursors.

Gal-3 and LAG-3 interract to affect cellular phenotype and properties
An interesting result that further contextualizes what has been previously
published is that the glycoprotein Gal-3 functions as a ligand for LAG-3. Although the
binding of these two molecules was not directly tested in this study, we found evidence
from co-culture FACS analysis that the level of Gal-3-dependent IL-10 and Foxp3
expression is affected by the presence or absence of LAG-3. Relative to LAG-3+/+ cell
cultures, knockout cell cultures saw the relative expressions of IL-10 and Foxp3 increase
from 3.49% and 5.04%, respectively, to 7.94% and 10.40%. The highest expression
(10.40%) occurred when LAG-3 was absent and Gal-3 was present, suggesting that LAG3 may be inhibiting receptor expression induced by Gal-3 and that the absence of LAG-3
accelerates differentiation, as discussed earlier. Interestingly, LAG-3 showed an even
stronger effect in the case of PD-1 expression: Gal-3-dependent induction of PD-1 on
CD4 cells only occurred in the absence of LAG-3. While it has been previously reported
that Gal-3 interacts with LAG-3 to suppress lymphocytes (27, 28), it also appears based
on this work that LAG-3 can block the downstream effects of Gal-3 in this cytokine
environment.

Distinguishing the isoform and cellular types responsible for LAG-3’s effects
The adoptive transfer experiments further demonstrate that the effects of surfacebound LAG-3 appear to eclipse those of soluble LAG-3 for transplant outcomes.
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Furthermore, even the cell type on which LAG-3 is expressed appears to influence the
both skin graft rejection speed and memory response. Mice with LAG-3-competent T
cells from adoptive transfer injections experienced prolonged graft survival compared
with LAG-3-/- graft recipients that did not receive injections. However, it was LAG-3competent dendritic cells, rather than T cells, that were responsible for reduced antidonor response more than one month after skin engraftment.
An area that has not yet been fully explored in the literature is the role of tolerant
dendritic cell subsets in producing graft-protective microenvironments. As master
controllers and activators of cell classes, including T cells (49), dendritic cells are prime
candidates for the cell type that would exert a very powerful effect on differentiation of
CD4+ T cell precursors using LAG-3. One subtype of dendritic cells that are DNGR-1+
has been shown to be important for cross-priming of naïve CD8+ T cells and the optimal
production of tissue resident memory cells (50). It is possible that another subset of
dendritic cells analogously controls differentiation of naïve CD4+ T cells in a LAG-3
dependent process that modulates transplantation outcomes. In fact, LAG-3 has also
been shown to be important for the development and homeostasis of dendritic cells and
macrophages (8, 51), and LAG-3 is used by dendritic cells to influence the phenotypes
and properties of other cells (5). Interestingly, Gal-3, shown in this and prior studies to
interact with LAG-3, has also been reported to modulate the function and expansion of
dendritic cells and the CD8 T cells they activate (28, 52).
While prior studies have demonstrated that LAG-3 is important for
downregulating T cell activation and cellular proliferation (1-5), our results suggest that
LAG-3 may also play an additional role in T cell biology by governing the differentiation
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of naïve CD4+ T cells, both in rejection transplant models and tolerogenic transplant
models. Additionally, LAG-3’s role as a modulator of transplantation must also include
its effect via dendritic cells, whose biological pathways with respect to effects
downstream of LAG-3 require further exploration. Past studies have shown that LAG-3
is critical for dendritic cell activation and migration in some cases, but it is interesting
that LAG-3 in this study depressed the anti-donor response, which would be consistent
with either inhibition of dendritic cell activity or activation of an inhibitory dendritic cell
subset.
Overall, the primary contribution of this research to the area of transplantation
and the broader field of immunology is the suggestion that LAG-3 may have a role in
promoting T cell differentiation in a way that is separate from its roles in promoting the
activation and proliferation of T cells. This theory should be further substantiated and
explored in related immunological research areas, such as tumor biology and infectious
diseases. An additional contribution of this research to the field is the finding that
targeting LAG-3 alone is likely to be insufficient in adequately mediating either tolerance
or rejection, because of its competing properties. Rather, LAG-3 should be explored as a
complementary therapy that eases the burden of broad immunosuppressives or other
drugs that are aggressively antagonistic to the patient’s systemic health.

Study Limitations & Future Directions
While the six conclusions generated by this study have produced novel results that
can further illuminate our collective understanding of LAG-3 and its role in
transplantation, there are aspects of the study results that need to be explored further.
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First, the histologic results demonstrating vasculopathy should be stained to quantify the
extent to which that antibody- or complement-mediated rejection are contributing to graft
failure, as this may suggest alternative molecular mechanisms corresponding to LAG-3
deletion. Second, the role of Tr1 cells should be more definitively explored in more
precise culturing experiments. Due to time and resource constraints, we were not able to
definitively identify the cultured T cells as Tr1 cells, due to a lack of CD49b expression.
Because CD49b is a widespread cellular integrin alpha subunit, one would expect that it
would not be broadly expressed on T cells cultured in vitro because they lack the
appropriate microenvironment stimuli necessary for promoting expression of migration
ligands and receptors. It does appear that the expression of other functional Tr1 markers,
LAG-3 (present) and Foxp3+ (absent), was consistent in the cell populations identified in
our study as with those published in the literature (9). Third, the interaction of Gal-3 and
LAG-3 should be further explored to determine whether one molecule directly affects the
induction of the other, possibly by using FACS sorting analysis. Fourth, the adoptive
transfer experiments used isolated dendritic cells, which were the basis for our study
conclusions that dendritic cells are responsible for LAG-3-mediated memory control, but
the isolation kits used do not reliably distinguish between dendritic cells and other
antigen-presenting cells such as B cells. Experiments should be conducted to tease apart
the separate contributions of each.
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